Fulcrum Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Fulcrum Therapeutics, Inc. (FULC) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Operating Activities
Net Income-9.73-97.34-109.87-80.85-70.82-82.68
Depreciation & Amortization1.592.172.412.522.382.05
Stock Based Compensation14.5514.8013.3511.077.350.00
Change in Working Capital-4.25-4.61-3.09-11.897.5011.27
Change in Accounts Receivable-1.56-0.313.41-1.11-2.530.00
Change in Accounts Payable-1.59-0.85-1.180.971.770.00
Change in Other Working Capital-1.10-2.52-1.551.410.380.00
Other Operating Activities-4.398.100.0010.636.9729.87
Net Cash from Operating Activities-2.22-90.97-97.05-78.48-53.66-39.48
Investing Activities
Capital Expenditures-0.28-0.51-1.96-1.71-1.340.94
Purchases of Investments-178.59-194.8914.38-216.23-55.800.00
Sales/Maturities of Investments211.10158.7114.3888.28-55.800.00
Other Investing Activities0.000.00165.5388.2868.470.00
Net Cash from Investing Activities32.23-36.6912.41-129.67-57.14-0.94
Financing Activities
Debt Repayment0.000.000.00-0.02-0.05-0.05
Common Stock Issued2.75117.3584.32182.8671.3864.42
Other Financing Activities0.000.0080.80182.86-0.190.00
Net Cash from Financing Activities2.75118.1284.32186.5171.1364.34
Summary
Net Change in Cash32.76-9.54-0.31-21.64-39.6623.92
Cash at Beginning of Period26.6636.1936.5058.1497.8173.89
Cash at End of Period59.4126.6635.4136.5096.7197.77
Free Cash Flow-2.50-91.47-99.01-80.19-55.00-40.43
Supplemental Disclosures
Interest Paid0.000.000.000.000.000.01